Houston--(Feb. 16, 2004)--Amylin, a hormone secreted by the same cells that produce insulin in the pancreas, prevents bone loss, said Baylor College of Medicine researchers and an international group of collaborators in a report in today's issue of the Journal of Cell Biology.
The finding may point the way toward treatments for osteoporosis, a disease of low bone mass that usually affects post-menopausal women but that is also observed in Type 1 diabetes patients, said Dr. Gèrard Karsenty, professor of molecular and human genetics at Baylor College of Medicine (BCM) in Houston and senior author.
"If osteoporosis in diabetes is associated with the absence of amylin, this finding has therapeutic implications," he said.
Amylin, a member of the calcitonin hormone family, inhibits bone loss or resorption. It is secreted by the pancreatic ß-cells at the same as insulin. Type 1 diabetics no longer produce insulin or amylin because their ß-cells no longer function. Mice who lack amylin have less bone mass than those who produce the hormone because they destroy bone more rapidly as it is seen in classical osteoporosis said Karsenty. Perhaps, he said, finding a way to replace amylin will enable physicians in the future to prevent osteoporosis in Type I diabetes and possibly in other forms of osteoporosis.
The finding extends understanding of the connection between metabolic hormones and bone mass, he said. Previously, Karsenty and his team had demonstrated that leptin, a hormone associated with weight control, affects bone formation through a brain relay.
Source: Eurekalert & othersLast reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.
The time is always right to do what is right.
-- Martin Luther King, Jr.